SynthesisScientific reports2025
The serum platelet-to-lymphocyte ratio as a predictor of outcomes in bladder cancer patients: an updated meta-analysis.
Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is conflicting evidence regarding the association between platelet-lymphocyte ratio (PLR) and the prediction of outcomes in bladder cancer (BCa). Due to the rapidly increasing availability of data to explore this issue, this updated meta-analysis investigates how pretreatment PLR influences the outcomes of BCa. Literature was retrieved from Embase, Cochrane Library, Web of Science, and PubMed from 2015 to April 2025. The 95% confidence intervals (CIs) and pooled hazard ratio (HR) have been employed in the exploration of the link across BCa prediction and PLR. The 95% CIs and pooled odds ratios (ORs) examined the connection between PLR and clinicopathological features of BCa. Subgroup analysis and meta-regression were conducted to identify the main sources of heterogeneity. Sensitivity analysis was used to assess the robustness of the results. The Egger's test and "trim and fill" method have been used in evaluating publication bias. This study incorporated 20 studies comprising 5,594 participants. Elevated PLR was conspicuously linked to inferior overall survival (OS) (HR = 1.51, 95% CI 1.23-1.85, P < 0.001) and recurrence-free survival (RFS) (HR = 1.68, 95% CI 1.26-2.24, P < 0.001). A marginally significant association was observed between high PLR and progression-free survival (PFS) (HR = 1.61, 95% CI1.00-2.59, P = 0.052). No strong correlation between PLR and cancer-specific survival (CSS) (HR = 1.14, 95% CI 0.96-1.35, P = 0.138). Additionally, elevated PLR was significantly associated with tumor stage ≥ T2 (OR = 1.92, 95% CI 1.24-2.97, P = 0.003). The PLR can be regarded as an indicative predictor of the destitution of individuals suffering from BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.